Cidara Therapeutics (CDTX) and Vaxart (VXRT) Financial Survey

Cidara Therapeutics (NASDAQ:CDTX) and Vaxart (NASDAQ:VXRT) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, valuation, institutional ownership, earnings, analyst recommendations, risk and profitability.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Cidara Therapeutics and Vaxart, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cidara Therapeutics 0 0 4 0 3.00
Vaxart 0 0 0 0 N/A

Cidara Therapeutics presently has a consensus target price of $12.33, suggesting a potential upside of 270.37%. Given Cidara Therapeutics’ higher probable upside, research analysts plainly believe Cidara Therapeutics is more favorable than Vaxart.

Valuation and Earnings

This table compares Cidara Therapeutics and Vaxart’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Cidara Therapeutics N/A N/A -$55.72 million ($3.18) -1.05
Vaxart $8.90 million 2.41 -$3.40 million N/A N/A

Vaxart has higher revenue and earnings than Cidara Therapeutics.

Profitability

This table compares Cidara Therapeutics and Vaxart’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Cidara Therapeutics N/A -91.51% -68.87%
Vaxart -330.79% -198.56% -40.81%

Risk and Volatility

Cidara Therapeutics has a beta of 1.82, suggesting that its stock price is 82% more volatile than the S&P 500. Comparatively, Vaxart has a beta of -0.03, suggesting that its stock price is 103% less volatile than the S&P 500.

Institutional & Insider Ownership

65.2% of Cidara Therapeutics shares are owned by institutional investors. Comparatively, 9.2% of Vaxart shares are owned by institutional investors. 15.2% of Cidara Therapeutics shares are owned by insiders. Comparatively, 44.8% of Vaxart shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Cidara Therapeutics beats Vaxart on 6 of the 10 factors compared between the two stocks.

About Cidara Therapeutics

Cidara Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of anti-infectives for the treatment of diseases. Its lead product candidate is rezafungin acetate, a molecule in the echinocandin class of antifungals for the treatment and prevention of serious invasive fungal infections, including candidemia and invasive candidiasis, fungal infections associated with high mortality rates. It is also developing antibody-drug conjugates for multidrug-resistant bacterial infections that directly kill pathogens and also direct a patient's immune system to attack and eliminate bacterial, fungal, or viral pathogens. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in June 2014. Cidara Therapeutics, Inc. was founded in 2012 and is headquartered in San Diego, California.

About Vaxart

Vaxart, Inc., a clinical-stage company, focuses on developing oral recombinant vaccines based on its proprietary oral vaccine delivery platform. The company's platform delivers various recombinant protein antigens, such as those used in influenza, hepatitis B, and human papilloma virus (HPV) vaccines, as well as other recombinant vaccines. Its development programs include oral tablet vaccines that are designed to protect against norovirus, seasonal influenza, and respiratory syncytial virus, as well as a therapeutic vaccine for HPV. The company is headquartered in South San Francisco, California.

Receive News & Ratings for Cidara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cidara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply